Skip to Main Content

Paper Details

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Neurology
166
2021
Author NameAffiliation
Jan HillertUniversity of Melbourne, Australia Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Royal Melbourne Hospital, France Karolinska Institutet (T.S.), Sweden Biomedical Research Institute-Data Science Institute (L.G., Hasselt University, University Medical Center Gottingen, Swansea University, Washington University in St. Louis, MO Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Central Clinical School, Monash University, Australia Al-Amiri Hospital (R.A.), Kuwait Dokuz Eylul University (S.O.), Hospital Universitario de CEMIC RELACOEM (J.I.R., Menzies Institute for Medical Research, University Hospital Rigshospitalet, Denmark Universidade Estadual Paulista (D.B.), Faculdade de Medicina, Brazil Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Argentina Imperial College London (R.S.N.) Swansea University (R.S.N.), Hospital Britanico de Buenos Aires, (Cemcat) Vall d'Hebron Institut de Recerca (A.Z., Vall d'Hebron Hospital Universitari Universitat Autonoma de Barcelona (A.Z., Spain and Institute of Experimental Neurology (G.C.)
Yves MoreauUniversity of Melbourne, Australia Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Royal Melbourne Hospital, France Karolinska Institutet (T.S.), Sweden Biomedical Research Institute-Data Science Institute (L.G., Hasselt University, University Medical Center Gottingen, Swansea University, Washington University in St. Louis, MO Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Central Clinical School, Monash University, Australia Al-Amiri Hospital (R.A.), Kuwait Dokuz Eylul University (S.O.), Hospital Universitario de CEMIC RELACOEM (J.I.R., Menzies Institute for Medical Research, University Hospital Rigshospitalet, Denmark Universidade Estadual Paulista (D.B.), Faculdade de Medicina, Brazil Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Argentina Imperial College London (R.S.N.) Swansea University (R.S.N.), Hospital Britanico de Buenos Aires, (Cemcat) Vall d'Hebron Institut de Recerca (A.Z., Vall d'Hebron Hospital Universitari Universitat Autonoma de Barcelona (A.Z., Spain and Institute of Experimental Neurology (G.C.)
Yves MoreauUniversity of Melbourne, Australia Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Royal Melbourne Hospital, France Karolinska Institutet (T.S.), Sweden Biomedical Research Institute-Data Science Institute (L.G., Hasselt University, University Medical Center Gottingen, Swansea University, Washington University in St. Louis, MO Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Central Clinical School, Monash University, Australia Al-Amiri Hospital (R.A.), Kuwait Dokuz Eylul University (S.O.), Hospital Universitario de CEMIC RELACOEM (J.I.R., Menzies Institute for Medical Research, University Hospital Rigshospitalet, Denmark Universidade Estadual Paulista (D.B.), Faculdade de Medicina, Brazil Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Argentina Imperial College London (R.S.N.) Swansea University (R.S.N.), Hospital Britanico de Buenos Aires, (Cemcat) Vall d'Hebron Institut de Recerca (A.Z., Vall d'Hebron Hospital Universitari Universitat Autonoma de Barcelona (A.Z., Spain and Institute of Experimental Neurology (G.C.)
Helmut ButzkuevenUniversity of Melbourne, Australia Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Royal Melbourne Hospital, France Karolinska Institutet (T.S.), Sweden Biomedical Research Institute-Data Science Institute (L.G., Hasselt University, University Medical Center Gottingen, Swansea University, Washington University in St. Louis, MO Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Central Clinical School, Monash University, Australia Al-Amiri Hospital (R.A.), Kuwait Dokuz Eylul University (S.O.), Hospital Universitario de CEMIC RELACOEM (J.I.R., Menzies Institute for Medical Research, University Hospital Rigshospitalet, Denmark Universidade Estadual Paulista (D.B.), Faculdade de Medicina, Brazil Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Argentina Imperial College London (R.S.N.) Swansea University (R.S.N.), Hospital Britanico de Buenos Aires, (Cemcat) Vall d'Hebron Institut de Recerca (A.Z., Vall d'Hebron Hospital Universitari Universitat Autonoma de Barcelona (A.Z., Spain and Institute of Experimental Neurology (G.C.)
Giancarlo ComiUniversity of Melbourne, Australia Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Royal Melbourne Hospital, France Karolinska Institutet (T.S.), Sweden Biomedical Research Institute-Data Science Institute (L.G., Hasselt University, University Medical Center Gottingen, Swansea University, Washington University in St. Louis, MO Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Central Clinical School, Monash University, Australia Al-Amiri Hospital (R.A.), Kuwait Dokuz Eylul University (S.O.), Hospital Universitario de CEMIC RELACOEM (J.I.R., Menzies Institute for Medical Research, University Hospital Rigshospitalet, Denmark Universidade Estadual Paulista (D.B.), Faculdade de Medicina, Brazil Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Argentina Imperial College London (R.S.N.) Swansea University (R.S.N.), Hospital Britanico de Buenos Aires, (Cemcat) Vall d'Hebron Institut de Recerca (A.Z., Vall d'Hebron Hospital Universitari Universitat Autonoma de Barcelona (A.Z., Spain and Institute of Experimental Neurology (G.C.)
  • 1 - 5

Datasets